EyePoint Pharmaceuticals
Tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 7 % | 12 % | 11 % | (6 %) | (33 %) | (39 %) | 1388 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (142 %) | (181 %) | (147 %) | (299 %) | 918 % | (445 %) | (4 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (158 %) | (247 %) | (154 %) | (302 %) | (718 %) | (1190 %) | (73 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 77 % | 120 % | 141 % | 307 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company dedicated to developing and commercializing innovative ophthalmic products and technologies aimed at preventing blindness and treating serious eye diseases. The company focuses on areas with high unmet medical needs, providing solutions that significantly improve the lives of patients suffering from severe eye conditions. EyePoint operates in the pharmaceutical market, targeting ophthalmologists and healthcare providers who treat eye disorders. The business model revolves around the development, approval, and commercialization of sustained release drug products, leveraging proprietary technologies like Durasert™ and Verisome™. Revenue is generated through product sales, licensing agreements, and strategic partnerships.
Keywords: ophthalmic, biopharmaceutical, blindness prevention, sustained release, drug products, Durasert, Verisome, eye diseases, innovation, commercialization.
Tech stack
Investments by EyePoint Pharmaceuticals
Edit